Focus: Marea Therapeutics is a public biotech company focused on developing treatments for cardiometabolic diseases, with a pipeline concentrated in metabolic disorders and rare endocrine conditions. Founded in 2018 and headquartered in South San Francisco, the company operates at an early clinical stage with two lead programs.
Profile data last refreshed 16m ago · AI intelligence enriched 3w ago
Stable — net -2 jobs in 30d
1 added, 3 removed. Backfill posture.
Best suited for early-career or mid-level professionals seeking hands-on involvement in clinical program development at a focused, public-stage biotech; higher execution risk than diversified competitors.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Marea Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Marea Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Marea Therapeutics Presents Phase 1 Data Supporting Potential Best-in-Disease Profile of MAR002 for the Treatment of Acromegaly at ENDO 2026 - Yahoo Finance
Marea Therapeutics Presents Phase 1 Data Supporting Potential Best-in-Disease Profile of MAR002 for the Treatment of Acromegaly at ENDO 2026 Yahoo Finance
Marea Therapeutics to Present Data from Phase 1 Study of MAR002 for the Treatment of Acromegaly at ENDO 2026 - Business Wire
Marea Therapeutics to Present Data from Phase 1 Study of MAR002 for the Treatment of Acromegaly at ENDO 2026 Business Wire
Fulcrum taps ex-Graphite Bio CEO with Oxbryta experience for board - Stock Titan
Fulcrum taps ex-Graphite Bio CEO with Oxbryta experience for board Stock Titan
Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight - Nasdaq
Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight Nasdaq
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo